Middle East & AfricaENPublic regulatory overview
Kuwait
Market Overview Population: Approximately 4.8 million (2024; approximately 70% are expatriates) Healthcare System: Highly public — the Ministry of Health (MOH) directly operates a...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAStrong benefitFDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingPartial / emerging acceptanceNMPA is an emerging reference factor here: it may be accepted or considered for selected products, documents, or review discussions, but the scope must be verified before filing.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Kuwait
- Product line: Medical devices
- Regulator / source: Regulatory Maturity: Medium; the MOH Medical Device Registration Department is fully functional; the PRISM online registration system is live; the GCC MedDev harmonization mechanism is progressively advancing; a regional unified registration pathway is still under development
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 4.8 million (2024; approximately 70% are expatriates)
- Healthcare System: Highly public — the Ministry of Health (MOH) directly operates a nationwide hospital and clinic network, providing healthcare services free of charge to citizens; coverage for expatriate residents is limited; the private healthcare sector is growing rapidly; per capita healthcare expenditure is high; government procurement is the primary channel for medical devices
- Market Characteristics: A small-volume, high-value market; government procurement dominates (MOH Central Medical Stores is the largest buyer); high openness to advanced medical technology; virtually completely import-dependent; policy is highly coordinated with other GCC member states (Saudi Arabia, UAE, Qatar, etc.); Saudi SFDA registration carries important reference value
- Regulatory Maturity: Medium; the MOH Medical Device Registration Department is fully functional; the PRISM online registration system is live; the GCC MedDev harmonization mechanism is progressively advancing; a regional unified registration pathway is still under development
Regulatory Authority
- Competent Authority: Kuwait Ministry of Health (MOH / وزارة الصحة), through the Department of Pharmaceutical Affairs and Drug Control / قطاع الشؤون الصيدلانية وأنشطة الدواء; medical device registration is handled by the Medical Devices Registration Department
- Official Portal: https://www.moh.gov.kw; Medical Device Registration System: PRISM (Product Registration Information System for Medical Devices), accessible via the MOH official website portal
- Key Regulations:
- Ministerial Decree No. 341/2005 (Medical Device Registration Decree and amendments)
- Kuwait Drug Law and Pharmaceutical Regulations (including Medical Device sections)
- GCC Medical Devices Technical Regulations (GCC regional medical device technical regulations; harmonization framework)
- GCC MedDev Technical Committee Resolutions
- MOH Circular Letters (MOH circulars, continuously publishing technical requirement updates)
Device Classification System
| Local Class | Risk Level | EU Equivalent | FDA Equivalent | Description |
|---|---|---|---|---|
| Class I | Low risk | EU Class I / FDA Class I | Simplified registration or notification | |
| Class II | Low-medium risk | EU Class IIa / FDA Class II | Standard registration; Technical File required | |
| Class III | Medium-high risk | EU Class IIb / FDA Class II–III | Full technical review | |
| Class IV | High risk | EU Class III / FDA Class III | Most rigorous review; complete clinical evidence required |
Classification follows GCC unified classification rules (based on the GHTF framework), essentially consistent with Saudi SFDA classification, facilitating unified GCC regional registration strategy planning.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.